Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04408638 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04408638 · ClinicalTrials.gov record · last posted 2026-07-07

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

StatusActive, Not Recruiting
PhasePhase 3
Started2021-02-23
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL.

Amendment record 67 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 67 times since 2020-05-26; most recent amendment 2026-07-03. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-07-26
Status change Recruiting→Active, Not Recruitingv56
2024-05-31
Status change Active, Not Recruiting→Recruitingv54
2024-05-03
Status change Recruiting→Active, Not Recruitingv53
2023-09-01
Status change Active, Not Recruiting→Recruitingv43
2023-08-04
Status change Recruiting→Active, Not Recruitingv42
2023-07-07
Status change Active, Not Recruiting→Recruitingv41
2023-05-25
Status change Recruiting→Active, Not Recruitingv40
2021-03-01
Status change Not Yet Recruiting→Recruitingv10
Trial Details
NCT Number NCT04408638
Lead Sponsor Hoffmann-La Roche
Conditions Diffuse Large B-cell Lymphoma
Enrollment 270 participants
Start Date 2021-02-23
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-07